The FDA has approved the first oral treatment for peanut allergy in children aged 4 to 17 years. Palforzia (manufactured by Aimmune Therapeutics) is a powder made from peanuts, consumed by patient in a macrodosing regimen spread over several months.
At present the medication is only available through a special FDA Risk Evaluation and Mitigation Strategy. Every powdered dose contains a fraction (around 1/600 of a peanut), to be mixed with a small amount of regular food.
“For those of us who grew up on peanut butter and jelly sandwiches, it’s encouraging to see a treatment option for parents,” said Benjamin Ticho, MD of Ticho Eye Associates. “Hopefully this will eventually reduce the stress experienced by parents of peanut-sensitive children.”